TP53 and non-small cell lung carcinoma: In 2019, La Fleur and colleagues had already analyzed a cohort of patients who underwent surgery for early-stage NSCLC, and they found a worse prognosis in individuals with TP53 mutations, thus reinforcing the results of our study [14].